Veterinary Warning Letters

Letter Cites Unapproved Animal Drugs, Misbranding, and Antimicrobial Stewardship Concerns

The U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) has issued a Warning Letter to The Fish Aid, an online distributor of antibiotics marketed for aquarium fish and birds, alleging the company illegally marketed numerous unapproved and misbranded new animal drugs through its website.

The April 3, 2026, warning letter identifies multiple antibiotic products, including amoxicillin, azithromycin, cephalexin, ciprofloxacin, clindamycin, doxycycline, metronidazole, penicillin, sulfamethoxazole/trimethoprim, and others, that FDA says were offered for treating bacterial infections in aquarium fish and birds without approved, conditionally approved, or indexed animal drug applications.

More than an approval issue

Although the warning letter focuses on marketing unapproved new animal drugs, FDA’s concerns extend well beyond product approval.

Many of the products cited contain antimicrobials considered medically important to human medicine. FDA emphasized that these drugs should be used only under the supervision of a licensed veterinarian and expressed concern that over-the-counter availability contributes to antimicrobial resistance affecting both animal and human health.

This reflects FDA’s continuing effort to promote antimicrobial stewardship across both veterinary and human medicine.

Registration and listing violations

FDA also alleged that the products were misbranded because they had not been properly listed with the agency and were not manufactured in FDA-registered establishments, as required under the Federal Food, Drug, and Cosmetic Act.

Establishment registration and drug listing serve important regulatory functions by allowing FDA to identify manufacturers, maintain product inventories, and support oversight activities throughout the supply chain.

Minor species still require regulatory compliance

An interesting aspect of the communication is FDA’s discussion of minor species.

Aquarium fish and pet birds qualify as minor species under the Federal Food, Drug, and Cosmetic Act. While Congress created an Index of Legally Marketed Unapproved New Animal Drugs to provide a streamlined pathway for certain products intended for minor species, FDA noted that the products marketed by The Fish Aid had not been approved, conditionally approved, or index listed.

The agency specifically encouraged the company to explore the index listing pathway if it intends to continue marketing products for eligible nonfood-producing minor species.

Regulatory implications

This Warning Letter demonstrates several important regulatory principles for companies operating in the animal health industry.

First, products intended to diagnose, cure, mitigate, treat, or prevent disease in animals are generally considered animal drugs under federal law regardless of whether they are marketed for companion animals, aquarium fish, birds, or livestock.

Second, products intended for minor species are not exempt from FDA oversight. Instead, manufacturers may have access to alternative regulatory pathways, such as conditional approval or the Minor Use and Minor Species (MUMS) Index, depending on the intended use.

Third, FDA continues to view antimicrobial stewardship as a significant public health priority. The agency’s emphasis on veterinary oversight reflects ongoing efforts to reduce unnecessary antimicrobial use and slow the development of antimicrobial resistance.

MDP perspective

This warning letter illustrates that veterinary regulatory compliance extends far beyond manufacturing quality systems.

Successful compliance programs must also address product classification, regulatory approval strategy, establishment registration, drug listing, labeling and promotional claims, veterinary oversight requirements, antimicrobial stewardship, and public health considerations.

For organizations developing products intended for companion animals or minor species, understanding the appropriate FDA regulatory pathway early in product development can help avoid significant enforcement actions while facilitating legal market access.